Menu

Detecting Protein Clumps

A synthetic genetic tool called yTRAP allows high-throughput detection of protein aggregates in cells.  

Feb 1, 2018
Ruth Williams

AGGREGATION ASSAY: To detect clumping of a protein of interest, express it together with a synthetic transcriptional activator domain (grey). If the protein remains soluble, the reporter gene (green), which is under the control of a synthetic promoter that corresponds to the activator, will be expressed. If the proteins clump together, it will not. © GEORGE RETSECK
See full infographic: WEB

The aggregation of cellular proteins into insoluble clumps is a hallmark of many diseases, including Alzheimer’s, Parkinson’s, systemic amyloidosis, prion diseases, and type 2 diabetes. Protein agglomeration can also be a feature of normal cellular functions, such as signal transduction, synapse modification, and the regulation of RNAs during cellular stress.

Tools for studying such physiological and pathological protein aggregations, however, are limited, explains biomedical engineer Ahmad Khalil of Boston University. The principal options for researchers, he says, are either to destroy cells and analyze their innards for protein aggregates, or append a fluorescent tag to the proteins of interest within cells and view the formation of clumps (bright spots) with a microscope.

While this second option maintains the protein’s normal physiological surroundings, Khalil says, “inherently it is not a very high-throughput way of studying this phenomenon.”

Khalil and colleagues’ new approach, called yeast transcriptional reporting of aggregating proteins (yTRAP), allows for high-throughput analysis and doesn’t destroy cells. An aggregation-prone protein of interest is first fused to a synthetic transcriptional activator, which can drive gene expression from a synthetic promoter only when the protein is not aggregated. Linking the synthetic promoter to a fluorescent reporter allows easy identification and, if desired, sorting of cells with and without aggregates.

The team has used yTRAP to detect accumulations of prions and other proteins in yeast; to perform a high-throughput screen for aggregation-preventing mutants; and to identify cells that “remembered” an environmental stimulus (heat)—using a yeast strain engineered to express a stably aggregating prion under the control of a heat-responsive promoter.

The assay “can inform us about a very important cellular process,” says Madan Babu of the MRC Laboratory of Molecular Biology in Cambridge, U.K., who was not involved with the project. But it also “can be applied to a number of different questions,” he says. “It’s a bit of a tour de force.” (Cell, 171:966–79, 2017) 

AGGREGATION DETECTION TECHNIQUE HOW IT WORKS ASSAY EQUIPMENT HIGH THROUGHPUT CAPACITY CELL TYPES
Fluorescent tagging of aggregation-prone protein
 
Proteins are fluorescently tagged—either by being engineered as fluorescent fusion proteins, or by applying fluorescent antibodies. Soluble proteins appear as diffuse fluorescence, while aggregates appear as bright spots.
 
Fluorescence
microscope
 
Poor Any
yTRAP Proteins are fused to a synthetic transcriptional activator. The fusion protein is then expressed in cells where corresponding synthetic promoters drive expression of reporters. Soluble proteins activate the reporter, while aggregated proteins do not. Fluorescence microscope, flow cytometer, fluorescence-
activated cell sorter (FACS), or fluorescence microplate reader
Good Limited to yeast so far, but future versions are planned
for other cell types

 

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.